Lisa Glasser, AstraZeneca, on a Needle-Free Flu Vaccine

AstraZeneca recently announced that FluMist Quadrivalent, the needle-free nasal spray flu vaccine, was approved for review by the US FDA. If approved, FluMist will be the first flu vaccine available to be self-administered – a major step towards revolutionizing how we protect against the flu. AstraZeneca’s submission of the supplemental biologics license application (sBLA) is expected to receive a regulatory decision from the FDA as soon as Q1 2024.

DocWire News spoke with Lisa Glasser, Head of US Medical Affairs, Vaccines and Immune Therapies, AstraZeneca to discuss this important milestone.